Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

This study is testing a new oral medication called APL-101 to see how well it works against certain types of advanced cancers, including non-small cell lung cancer. It is designed to target a specific gene mutation called 'MET' that helps cancer cells grow and spread.

This trial is for adults (18+) with specific types of advanced cancer where the MET gene is behaving abnormally. You must have tried certain standard treatments or be newly diagnosed with specific lung cancer mutations, and you should not have taken MET-targeted medications before.

Participants will take APL-101 by mouth and have regular check-ups to see how the cancer responds to the treatment and how the body handles the medicine. Doctors will carefully monitor your health to ensure the treatment is safe and effective for you throughout the study.

The study is currently recruiting patients and is taking place at various research centers in Los Angeles, Tampa, and Boston. You can speak with your oncology team to see if one of these locations is accessible for you.